Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05271318 |
| Title | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (PROTA) |
| Acronym | PROTA |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | TILT Biotherapeutics Ltd. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | FIN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Mayo Clinic | RECRUITING | Rochester | Minnesota | 55905 | United States | Details |
| Northwell Heatlh/Lenox Hill Hospital | RECRUITING | New York | New York | 10075 | United States | Details |
| Docrates Cancer Center | ACTIVE_NOT_RECRUITING | Helsinki | 00180 | Finland | Details |